Lexaria Bioscience Corp. has expanded its intellectual property portfolio to 60 granted patents worldwide, receiving six new patents across key markets that strengthen its position in drug delivery technology. The company's growing patent protection now covers major therapeutic areas including nicotine delivery, hypertension, epilepsy, and diabetes treatments, with recent approvals in Australia and the European Union representing significant market expansions.
The company received its first Australian patent in patent Family #20, covering compositions and methods for sublingual delivery of nicotine, where it already holds patents in the United States, Canada, and Japan. In patent Family #21, focused on compositions and methods for treating hypertension, Lexaria secured its first European Union patent, entering what is considered the world's second-largest hypertension market following the United States.
For epilepsy treatments in patent Family #24, the company received two new Australian patents and one European Union patent, bringing its total intellectual property in this family to six U.S. patents, four Australian patents, and one European Union patent. In patent Family #27, covering compositions and methods for treating diabetes, Lexaria obtained one new U.S. patent, bringing its total in this family to two U.S. patents, which the company considers particularly important given recent successes in the GLP-1 sector.
Lexaria's patent strategy follows a rigorous research process where initial hypotheses are evaluated through existing scientific literature review, followed by animal and human testing to generate data supporting patent applications in international markets. The company emphasizes that only after patents are granted can it safely pursue commercial relationships to exploit its innovations. The company's DehydraTECH technology platform, which improves how drugs enter the bloodstream through oral delivery, forms the foundation of these patent families.
The expansion of Lexaria's patent portfolio to 60 granted patents represents a significant milestone in the competitive pharmaceutical technology sector, where intellectual property protection is crucial for commercial success and investor confidence. Strong patent positions in major markets like the European Union and Australia provide the company with greater leverage in potential licensing agreements and partnerships, while also creating barriers to entry for competitors in the drug delivery space.
Lexaria shareholders are reminded to vote their shares for the company's upcoming annual meeting scheduled for January 27, 2026. Stockholders holding common stock as of December 1, 2025, are entitled to vote, with proxy materials available online at https://www.colonialstock.com/LEXX2026. The company encourages shareholders to review the detailed proxy statement and annual report before the voting deadline of January 26, 2026.
